Skip to content
Scailyte
  • Company
  • Discovery Engine
  • Pipeline
  • AIomics: IBD program
  • Resources
  • News
×
  • Company
  • Discovery Engine
  • Pipeline
  • AIomics: IBD program
  • Resources
  • News
Get in touch
Scailyte
  • Company
  • Discovery Engine
  • Pipeline
  • AIomics: IBD Program
  • Resources
  • News
×
  • Company
  • Discovery Engine
  • Pipeline
  • AIomics: IBD Program
  • Resources
  • News
Get in touch
Scailyte
  • Company
  • Discovery Engine
  • Pipeline
  • AIomics: IBD Program
  • Resources
  • News
×
  • Company
  • Discovery Engine
  • Pipeline
  • AIomics: IBD Program
  • Resources
  • News
Scailyte
  • Company
  • Discovery Engine
  • Pipeline
  • AIomics: IBD program
  • Resources
  • News
×
  • Company
  • Discovery Engine
  • Pipeline
  • AIomics: IBD program
  • Resources
  • News
Get in touch

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

Delve deep into the transformative impact of ScaiVision, Scailyte’s pioneering platform, on the realm of CAR-T cell therapy for Diffuse Large B-Cell Lymphoma (DLBCL).

Continue reading
white paper

True precision medicine through single-cell science

Scailyte’s artificial intelligence-powered platform, ScaiVision, identifies disease signatures that predict drug efficacy and describe drug mode of action to improve clinical outcomes for patients with complex diseases.

Continue reading
white paper

Scailyte’s ScaiVision performs best-in-class at sample class prediction

ScaiVision performs as the best-in-class algorithm at identifying molecular biomarkers, which accurately predict clinical status of the samples. Analysis with ScaiVision unlocks an unparalleled level of high-resolution and clinically relevant discoveries in single-cell datasets.

Continue reading
white paper
Scailyte

Contact Information:

Scailyte AG
Lichtstrasse 35
4056 Basel
Switzerland

  • LinkedInCreated with Sketch.
  • D3255223-CCD2-41A0-AFD7-7F9CA3058D9C

 

USA Contact Information:
Scailyte AG
c/o swissnex Boston
420 Broadway,
Cambridge, MA 02138,
USA

Get in touch

  • Careers
  • Contact us
  • Home
  • Company
  • Resources
  • News
  • Our Discovery Engine
  • Our Pipeline
Scailyte
Contact Information:

Scailyte AG
WSJ-500.1.101
Lichtstrasse 35
4056 Basel
Switzerland

  • LinkedInCreated with Sketch.
  • D3255223-CCD2-41A0-AFD7-7F9CA3058D9C
  • Clinical IVD Pipeline
  • ScaiVision
  • Partnering
  • Home
  • About
  • News
  • Careers
  • Contact us

Scailyte 2026 © All rights reserved. Scailyte, ScaiVision and the Scailyte logo are registered trademarks.

Terms & Conditions

Dr. Peter Nestorov

Founder & Chief Executive Officer

Co-founder and Chief Executive Officer of Scailyte. He holds a PhD in genetics from the University of Basel and a degree in Biochemistry from the University of Tübingen.

During his PhD work, Dr. Nestorov pioneered the development and application of methods for single-cell analysis, which sparked his passion for this technology. In 2015, Dr. Nestorov joined Witec AG as Sales Specialist for single-cell and genomics technologies and successfully introduced the first commercial devices for single-cell analysis on the Swiss Life Science market. The interaction with biomedical researchers and the technological insight inspired Dr. Nestorov to start Scailyte and unlock the full clinical potential of single-cell data.

Mobile Menu Closed

Dr. Sarah Carl

Lead Data Scientist
is managing the Data Science division of Scailyte. She holds a PhD in Genetics and a Master’s degree in Developmental Biology from the University of Cambridge. Before joining Scailyte she was a post-doc and bioinformatician at the Friedrich Miescher Institute for Biomedical Research in Basel. At Scailyte she is leading the development of new applications and features of the internal data analysis platform, ScaiVision, and the data analysis of the clinical programmes.
Mobile Menu Closed

Anna Dimitrova, ACCA

Director Finance & Ops
Is the Director of Finance and Operations at Scailyte. She is an ACCA graduate with a Master’s degree in Finance and Banking from Sofia University. Before joining Scailyte she worked as Senior Audit Assistant at KPMG, Senior Business Consultant at PwC and as Finance Manager in a fast growing company in Bulgaria. At Scailyte she leads the finance, administration and internal operations of the company.

Pascal Winnen

CEO Hemex AG & Scailyte Board of Directors

Pascal is a co-founder and the CEO of HEMEX, a pharmaceutical, biotech and medical device consulting firm with offices in Switzerland, Germany and the USA. He holds a bachelor’s degree in Telecommunication Technologies from the University of Leuven (Belgium) and a master’s degree in Clinical Research from the Donau University in Krems (Austria). Pascal worked in various positions in the pharmaceutical and medtech industry.

From 2011 to 2015, Pascal worked for Finox Biotech, bringing one of the first biosimilar fertility treatments to the market in the EU and leading to the successful acquisition by Gedeon Richter for CHF 190 million. With his consulting firm HEMEX, Pascal has invested in multiple innovative life science startups, where he also advises on regulatory, clinical and marketing strategies, either as a senior consultant or as a board member.

Mobile Menu Closed

Dominique Mégret

Head of Swisscom Ventures & Scailyte Board of Directors
Dominique Mégret is head of Swisscom Ventures, which he started in 2007. He joined Swisscom in 2002 as head of the Group Strategy unit. Previously, Dominique Mégret was an entrepreneur in the United Kingdom, a strategy consultant in the European telecom industry and country manager for an IT company in Germany. He currently serves on the boards of Scailyte AG and Bloom SA. He is also an observer on the boards of Sophia Genetics and AVA Women.
Mobile Menu Closed

Prof. Dr. Manfred Claassen

Founder & Chief Scientific Advisor AI & Single-Cell Analysis
Co-founder and Chief Scientific Advisor at Scailyte. He holds degrees in both Biochemistry and Computer Science from the University of Tübingen and a PhD in the design and validation of proteome measurements from the ETH Zurich. He continued his academic path as a postdoctoral researcher at Stanford University’s Artificial Intelligence Lab focusing on research in machine learning for high dimensional single-cell biology, he moved back to Switzerland as an Assistant Professor at the ETH. During this time, the idea of establishing a company specialising in digital healthcare was conceived. Dr. Claassen was instrumental in conceptualizing the new company. He is now professor for clinical bioinformatics at the University of Tübingen, Germany in parallel with his role as scientific consultant for Scailyte.
Mobile Menu Closed
We use cookies to ensure that we give you the best experience on our website. By continuing to use this website you agree to our policies.